← Leaderboards
Neil P Shah
University Of California, San Francisco
$6,146,823
Attributed
$8,693,709
Total exposure
8
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2010–25$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,693,709 · 8
By mechanism
R01$8,011,499 · 4
P30$362,902 · 1
R41$285,792 · 1
P41$33,516 · 2
Top collaborators
- Hong-Yu Li9 shared
- Hong Yu Li1 shared
- Ahlam Nasser1 shared
Most similar at University Of California, San Francisco
Same institution · by research overlap
- Hong-Yu Li$3,813,256
- Catherine Choy Smith$4,365,274
- Nola M. Hylton$19,153,972
- Michelle Mintz$159,993
- Ahlam Nasser$54,807
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsResistanceDrug ResistanceTranslational StudyMolecularTargeted TreatmentHematologic NeoplasmsPhosphotransferasesMutationTyrosine Kinase InhibitorDiagnosisIn VitroPre-ClinicalSamplingProgramsClinical TrialsCellsLeukemiaInsightTherapeutic TargetClinical InvestigationChronic Myeloid LeukemiaImproved OutcomeKinase Inhibitor
Grant awards (30)
Development of Potent, Selective, Non-Myelotoxic FLT3 Inhibitors that Retain Efficacy Against Common Mechanisms of Resistance$652,744
R01 · FY2025 · CA · contact PI
Development of Potent, Selective, Non-Myelotoxic FLT3 Inhibitors that Retain Efficacy Against Common Mechanisms of Resistance$620,109
R01 · FY2024 · CA · contact PI
Development of Potent, Selective, Non-Myelotoxic FLT3 Inhibitors that Retain Efficacy Against Common Mechanisms of Resistance$639,689
R01 · FY2023 · CA · contact PI
Impact of myeloid leukemia associated mutations (ASXL1, DNMT3A, TET2, IDH1 and IDH2) on treatment responses among Chronic Myeloid Leukemia (CML) patients in Tanzania$109,614
R01 · FY2023 · CA · contact PI
Development of Potent, Selective, Non-Myelotoxic FLT3 Inhibitors that Retain Efficacy Against Common Mechanisms of Resistance$642,786
R01 · FY2022 · CA · contact PI
Hematopoietic Malignancies Program$87,279
P30 · FY2022 · CA · contact PI
Development of Potent, Selective, Non-Myelotoxic FLT3 Inhibitors that Retain Efficacy Against Common Mechanisms of Resistance$685,777
R01 · FY2021 · CA · contact PI
Hematopoietic Malignancies Program$79,592
P30 · FY2020 · CA · contact PI
Hematopoietic Malignancies Program$86,716
P30 · FY2019 · CA · contact PI
Discovery and Development of a Selective pan-FLT3-ITD Kinase Inhibitor Clinical Candidate for the Treatment of FLT3-ITD-Driven AML$358,560
R01 · FY2018 · CA
Hematopoietic Malignancies Program$86,469
P30 · FY2018 · CA · contact PI
Hematopoietic Malignancies Program$10,743
P30 · FY2018 · CA · contact PI
Hematopoietic Malignancies Program$8,603
P30 · FY2018 · CA · contact PI
Hematopoietic Malignancies Program$3,500
P30 · FY2018 · CA · contact PI
Discovery and Development of a Selective pan-FLT3-ITD Kinase Inhibitor Clinical Candidate for the Treatment of FLT3-ITD-Driven AML$358,560
R01 · FY2017 · CA
Crenolanib and ponatinib for the treatment of FLT3 mutant AML$328,888
R01 · FY2017 · CA · contact PI
Discovery and Development of a Selective pan-FLT3-ITD Kinase Inhibitor Clinical Candidate for the Treatment of FLT3-ITD-Driven AML$370,810
R01 · FY2016 · CA
Crenolanib and ponatinib for the treatment of FLT3 mutant AML$328,888
R01 · FY2016 · CA · contact PI
Mechanisms of resistance to clinically-effective FLT3 kinase inhibitors in AML$320,588
R01 · FY2016 · CA · contact PI
Discovery and Development of a Selective pan-FLT3-ITD Kinase Inhibitor Clinical Candidate for the Treatment of FLT3-ITD-Driven AML$369,332
R01 · FY2015 · CA
Crenolanib and ponatinib for the treatment of FLT3 mutant AML$328,629
R01 · FY2015 · CA · contact PI
Mechanisms of resistance to clinically-effective FLT3 kinase inhibitors in AML$320,588
R01 · FY2015 · CA · contact PI
Pre-IND study of PMT-254, a pan-FLT3 inhibitor for the treatment of FLT3 driven cancers.$285,792
R41 · FY2015 · CA · contact PI
Crenolanib and ponatinib for the treatment of FLT3 mutant AML$317,512
R01 · FY2014 · CA · contact PI
Mechanisms of resistance to clinically-effective FLT3 kinase inhibitors in AML$310,970
R01 · FY2014 · CA · contact PI
Crenolanib and ponatinib for the treatment of FLT3 mutant AML$325,515
R01 · FY2013 · CA · contact PI
Mechanisms of resistance to clinically-effective FLT3 kinase inhibitors in AML$301,352
R01 · FY2013 · CA · contact PI
Mechanisms of resistance to clinically-effective FLT3 kinase inhibitors in AML$320,588
R01 · FY2012 · CA · contact PI
UNDERSTANDING TONIC RELIANCE UPON BCR-ABL: A PHOSPHOPROTEOMIC APPROACH$24,684
P41 · FY2011 · RR · contact PI
UNDERSTANDING TONIC RELIANCE UPON BCR-ABL: A PHOSPHOPROTEOMIC APPROACH$8,832
P41 · FY2010 · RR · contact PI